Cognition Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Good afternoon, everyone. Welcome again to the next session with Cognition Therapeutics. I'm Ami Fadia; I cover neuroscience and targeted oncology here at Needham. And it's my pleasure to be hosting Lisa Ricciardi, who's the CEO of the company; as well as Jim O'Brien, who is the Chief Financial Officer. Lisa will be taking you through a presentation. (Conference Instructions)
With that, Lisa, please go ahead.
Thank you, Ami. A pleasure to be here. Thank you for including us at Needham's panel this afternoon. I was so eager to get to the forward-looking statement, now I'm struggling to get back to it. So here you have it. We completed our IPO in October and are delighted to have raised the money we need for our trials.
Brief background on our company. Neurodegenerative disorders, age-related neurodegenerative disorders, and specifically, the central nervous system as well as the retina, which in shorthand means Alzheimer's disease, dementia with
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |